NorthWest Biotherapeutics Inc (NWBO)

[sharpie510]

because I personally do believe DCVax-L does not typically help much after recurrence without surgery combined with DCVax-L. We know that only three such combinations occurred as of the March 2017 data. Anything after that would have been on patients in the trial with much later recurrence.

That is a great point as to why the late vaccination patients may not do as well. They had to take the vaccine made with the original gbm tumor, and not DCVax-L made with their new recurrent tumor. I think the compassionate cases outside of the trial that were recurrent gbm seemingly did well because they got DCVax-L made with their latest resected tumor. So, while in the trial, DCVax-L may not help much for the soc crossover patients after recurrence, outside the restrictions of the trial, recurrent gbm patients would likely be helped because their DCVax-L will be made with the latest tumor and treatment would not be delayed.